NVILE forecast ·
Merck (MRK) Stock Forecast: Next 30 Days
Over the next 30 days, the calibrated 80% price range for Merck (MRK) is $132.76 to $162.36, centered around an expected value of $146.81 from the current price of $145.89. Calibrated event-volatility modeling indicates an 8% probability of dropping more than 10% and a 13% probability of rising more than 10%. Price history alone carries no tested directional skill; recent Q3 earnings beats support fundamentals, but analyst estimate cuts and heavy insider selling create balanced 30-day risk.
Price now
$145.89
Nov 3, 2026
In 30 days
$146.81
NVILE forecast
Expected move
+0.6%
Range
$132.76–$162.36
What to do
- Adopt a range-bound tactical posture around the $132.76–$162.36 distribution rather than directional bets.Calibrated distribution models show low tail probabilities (8% drop >10%, 13% rise >10%) and absence of directional momentum.
- Monitor short volume normalization and hedge downside tail risk below $132.76.[2],[3]Elevated single-day short volume (47.0%) and $29.98M in recent insider sales suggest vulnerability to downside volatility.
Why
- MRK trades at $145.89, with calibrated 80% probability bands spanning $132.76 to $162.36 over the 30-day horizon.
- Wall Street 12-month consensus targets average $159.91 (range $105.00 to $186.00), implying 9.6% upside, despite recent downward EPS revisions.[5]
- MRK Q3 2026 earnings beat expectations and management raised full-year guidance, driving a 2.2% post-earnings rally.[6],[10]
- Keytruda and commercial execution remain solid, easing near-term profit squeeze concerns following strong Q3 results.[6],[10]
- Ongoing pipeline advancements, including the Moderna melanoma vaccine partnership and Verona Pharma acquisition, support long-term diversification.[1],[4],[7]
What could go wrong
- IRA price negotiations target Januvia (2026), Janumet (2027), Lenvima (2028), and potentially Keytruda in 2029, creating medium-term pricing headwinds.[8]
- Heavy insider selling totaling $29.98M over 90 days with zero insider buys signals caution among senior leadership.[2]
- Persistent challenges for Gardasil, especially weak demand in China, and earnings estimate cuts dampen near-term sentiment.[4],[9]
How it connects
- Merck & Co., Inc.acquired Verona Pharma plc to obtain OhtuvayreVerona Pharma plc[1]
- Merck & Co., Inc.acquired poultry biodevice developer TARGAN in July 2026TARGAN[8]
- Merck & Co., Inc.jointly developing mRNA cancer vaccine intismeran autogene withModerna, Inc.[9],[4],[7]
- Merck & Co., Inc.depends heavily on sales and lifecycle extensions ofKeytruda (pembrolizumab)[4],[8],[1]
- Merck & Co., Inc.markets and distributes vaccine productGardasil[9],[4]
- U.S. Department of Health and Human Services / CMSset price under IRA effective January 1, 2026 forJanuvia[8]
- U.S. Department of Health and Human Services / CMSexpected to select for government price setting in 2027Keytruda (pembrolizumab)[8]
- China Pharmaceutical Marketdepressed Gardasil revenues due to channel inventory and local competitionGardasil[9]
- Eli Lilly and Companycompetes for investor capital in large-cap biopharmaMerck & Co., Inc.[9]
NVILE's track record on this page
| Made | Forecast | Actual | Result |
|---|---|---|---|
| Nov 3, 2026 | $146.81 | Due Dec 3, 2026 | Pending |
Every published call is scored when it comes due. See all results →
Sources
- 1.Merck & Co., Inc. 10-K (2026-02-24) · sec.gov
- 2.Merck & Co., Inc. insider transactions (SEC Form 4) · sec.gov
- 3.MRK daily short-sale volume (FINRA) · finra.org
- 4.Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? · theglobeandmail.com
- 5.MRK Wall Street consensus: estimates, revisions, ratings, targets · finance.yahoo.com
- 6.Merck (MRK) Stock Rallies As Q3 Earnings Ease Profit Squeeze · finance.yahoo.com
- 7.VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results · reuters.com
- 8.Merck & Co., Inc. 10-Q (2026-08-07) · sec.gov
- 9.LLY vs. MRK: Which Stock Offers the More Compelling Investment Case? · theglobeandmail.com
- 10.Merck stock rises as Q3 earnings beat estimates, 2026 outlook raised · msn.com
Questions
What is the Merck forecast for the next 30 days?
NVILE's models put Merck at about $146.81 in 30 days, +0.6% from $145.89. Over the next 30 days, the calibrated 80% price range for Merck (MRK) is $132.76 to $162.36, centered around an expected value of $146.81 from the current price of $145.89. Calibrated event-volatility modeling indicates an 8% probability of dropping more than 10% and a 13% probability of rising more than 10%. Price history alone carries no tested directional skill; recent Q3 earnings beats support fundamentals, but analyst estimate cuts and heavy insider selling create balanced 30-day risk.
What price range does NVILE expect for Merck?
The forecast range is $132.76 to $162.36 over 30 days. Prices outside this range are possible; the range describes the model's scenarios, not a guarantee.
What could change the Merck outlook?
IRA price negotiations target Januvia (2026), Janumet (2027), Lenvima (2028), and potentially Keytruda in 2029, creating medium-term pricing headwinds. Heavy insider selling totaling $29.98M over 90 days with zero insider buys signals caution among senior leadership. Persistent challenges for Gardasil, especially weak demand in China, and earnings estimate cuts dampen near-term sentiment.
What should investors watch or do about Merck?
Adopt a range-bound tactical posture around the $132.76–$162.36 distribution rather than directional bets. Monitor short volume normalization and hedge downside tail risk below $132.76.
How accurate are NVILE forecasts?
Every forecast NVILE publishes is scored against the real price when it comes due, and the results are listed on NVILE's public accuracy ledger.
This page is generated by NVILE's research models from public sources and market data. It is not financial advice, and forecasts can be wrong.